FDA approves first injectable for cellulite

The FDA has approved Qwo for the treatment of moderate to severe cellulite in the buttocks of adult women, Endo International announced in a press release.

Qwo (collagenase clostridium histolyticum-aaes) is injected into the treatment area to release the fibrous septae enzymatically by targeting types 1 and 3 collagen, which could result in skin smoothing, the release said.

"Endo recognized a significant unmet need for an effective and non-invasive injectable treatment for cellulite, which led us to conduct the largest clinical trials in the history of cellulite investigation in the United States," said Matthew Davis, MD, RPh, senior vice president and chief medical officer of Endo. "Supported by rigorous research, testing and development processes, we are proud to have received FDA approval of the first injectable treatment for cellulite in the buttocks, and we look forward to delivering QWO to the aesthetics community and their adult female patients."

It is expected to be available in Spring 2021 in the United States. Side effects include injection site bruising, pain and areas of hardness and itching.